Transporter-Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions

Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance

(2015) Joris Vandenbossche et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin

(2010) Qing Li et al.   ACTA PHARMACOLOGICA SINICA

Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions

(2010) Giuliano Ciarimboli et al.   AMERICAN JOURNAL OF PATHOLOGY

Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity

(2010) Takanori Nakamura et al.   BIOCHEMICAL PHARMACOLOGY

Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II

(2010) Christine E. Staatz et al.   CLINICAL PHARMACOKINETICS

Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

(2010) Christina Fahrmayr et al.   DRUG METABOLISM REVIEWS

Pharmacogenetics of drug-induced liver injury

(2010) Stefan Russmann et al.   HEPATOLOGY

Sirolimus for calcineurin inhibitors in organ transplantation: contra

(2010) Paolo Cravedi et al.   KIDNEY INTERNATIONAL

SLCO1B1genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients

(2010) Hugues Michelon et al.   PHARMACOGENOMICS

Genetic Determinants of Drug-induced Cholestasis and Intrahepatic Cholestasis of Pregnancy

(2010) Christiane Pauli-Magnus et al.   SEMINARS IN LIVER DISEASE

Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins

(2009) Michael J. Knauer et al.   CIRCULATION RESEARCH

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

(2009) K K Filipski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics

(2009) N Picard et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

Blood−brain barrier transporters and response to CNS-active drugs

(2009) Bradley L. Urquhart et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

(2009) M. L. H. Vlaming et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms of renal anionic drug transport

(2008) Azza A.K. El-Sheikh et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Polymorphism in human organic cation transporters and metformin action

(2008) Hiroshi Takane et al.   PHARMACOGENOMICS